Connor, Clark & Lunn Investment Management Ltd. Rhythm Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 115,118 shares of RYTM stock, worth $12.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
115,118
Previous 50,557
127.7%
Holding current value
$12.3 Million
Previous $2.68 Million
171.62%
% of portfolio
0.03%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding RYTM
# of Institutions
249Shares Held
63.9MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$722 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$601 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$596 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$523 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$385 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $5.97B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...